New MolecuLight i:X® Upgrade Enables Faster, More Accurate Digital Wound Measurement

February 20, 2020 -i:X Platform’s Precise Wound Measurement, along with Fluorescence Imaging, for More Accurate Detection and Ongoing Documentation of Wounds

Toronto, CANADA – (February 20, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, released a significant upgrade to its i:X digital wound measurement

American Medical Association Issues Category lll CPT Code for Real-time Fluorescence Wound Imaging

February 13, 2020 -

Reimbursement Pathway Established for MolecuLight’s i:X Procedure in Wound Care

TORONTO, Canada – (February 13, 2020) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, announced that the American Medical Association (AMA) has issued two new CPT category lll codes to enable a

University Hospitals Ahuja Medical Center Physician First in Ohio to Use Wound Care Imaging Device in Clinical Setting

February 11, 2020 -

Portable MolecuLight i:X allows for imaging of harmful bacteria invisible to human eye

University Hospitals Ahuja Medical Center (UH) is the first clinical setting in Ohio using special technology to identify harmful bacteria, leading to healing for patients suffering from chronic wounds.

Windy Cole, DPM, Medical Director of the UH

MolecuLight Receives FDA 510(k) Clearance for its i:X® Handheld Fluorescence Imaging Device for Wound Management

December 5, 2019 -New FDA Approval Extends Label to Including the i:X’s® Detection of Bacteria and Digital Wound Measurement

TORONTO, Canada – (December 5, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of fluorescence in wounds, has received FDA 510(k) clearance for its i:X® handheld fluorescence imaging device

AMA Announces Approval for Category lll CPT Code for Real-time Fluorescence Wound Imaging

November 4, 2019 -Forthcoming Category lll CPT Code Reflects the Published Clinical Evidence and a Determination of Significant Value of Real-Time Fluorescence Imaging Across the Wound Care Treatment Pathway

TORONTO, Canada – (November 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, has

Clinical Results from the MolecuLight i:X® Fluorescence Imaging System are Featured in Two Clinical Talks and Seven Posters at the SAWC Fall 2019 Annual Conference

October 11, 2019 -

Multiple Trials Illustrate the Significant Clinical Benefit of MolecuLight’s Point-of-Care Fluorescence Imaging Device for Chronic Wound Management

LAS VEGAS, USA and TORONTO, Canada – (October 11, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds and its i:X point-of-care fluorescence imaging

Results from Clinical Studies using MolecuLight i:X® Fluorescence Imaging System Featured Prominently at the Wounds Canada 2019 Annual Conference

October 4, 2019 -

Point-of-Care Fluorescence Imaging for Chronic Wounds and its Significant Clinical Benefits are Featured at the Largest Canadian Wound Care Conference in 5 Clinical Talks and Posters

NIAGARA FALLS, Canada and TORONTO, Canada – (October 4, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization

Published Study Finds 9/10 Chronic Wound Patients Likely to Have Received More Appropriately Triaged Care with Information from the MolecuLight i:X® Imaging Device

September 13, 2019 -Study Highlights the Utility of Bacterial Fluorescence Imaging to Provide Real-Time Information to Clinicians on a Wound’s Bacterial Burden that Significantly Impacted Treatment Decisions Read More

Oxford Finance LLC Provides $7.5M USD Term Loan to MolecuLight® Inc. to Support Global Commercial Expansion

August 19, 2019 -

TORONTO, Canada – (August 20, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, announced it has secured a $7.5 million USD term loan from Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services